Using bispecific antibodies to advance cancer immunotherapy
pharmaphorum
NOVEMBER 2, 2021
The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.
52 
Let's personalize your content